AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02186197 — intervention group
Intervention type: OTHER
Intervention: Critical Care Ultrasound
Description: A critical care ultrasound exam will be performed on all patients included in this study
Study NCT03848910 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational device - Sound Processor
Description: At visit 1 the subjects will complete self-reported assessments with respect to pre-study experience using precursor Sound Processor (comparator). At visit 1 the subjects will then receive the Investigational device (Sound Processor) which should be used during the following 6 weeks. At visit 3 the subjects will complete self-reported assessments regarding Investigational device and participate in audiology tests regarding both Sound Processors, comparator and Investigational device. The subject shall decide their preferred choice made by selection between Investigational device and the comparator.
Study NCT00580112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 4 mg orally 24 hrs and 12 hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion on Day 1 to 3.
Study NCT00580112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin 1.3 mg/m\^2 intravenous infusion over 3-hrs every 3 weeks, on Day 1 of each cycle. Each cycle length will be 3 weeks.
Study NCT04051684 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transverse abdominal plane block
Description: Regional anesthesia team will perform a single shot TAP block with 0.5% ropivacaine 15-20 ml / side under ultrasound guided technique with blunt tipped, 21 gauge needle.
Study NCT04051684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Regional anesthesia team will perform a single shot TAP block with 0.5% ropivacaine 15-20 ml / side under ultrasound guided technique with blunt tipped, 21 gauge needle.
Study NCT01783002 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 11C-Methionine PET/CT scanning
Description: PET with the radiopharmaceutical carbon-11 methionine (11C-MET) has been considered to improve diagnosis due to a superior spatial resolution and higher specificity compared to other radiotracers such as 18F-FDG. For the 11C-MET PET/CT, the patient will receive an intravenous bolus injection of 11C-MET as manufactured at the BCCA production facility at a dose of 6 (0.16 mCi) MBq per kilogram but not to exceed 555 MBq (15 mCi).
Study NCT01783002 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT scanning
Description: For PET/CT scans, the patient will first receive an intravenous bolus injection of 18F-FDG as manufactured at the BCCA production facility in a dose determined by body weight but not to exceed 521 MBq (14.1 mCi). Our standard adult prescription (70kg adult) for 18F-FDG is 296 MBq (8.0 mCi). The target dose for body scans is increased by 59.2 MBq (1.6 mCi) for every 20 kg increase in body weight to a maximum target dose of 474 MBq (12.8 mCi).
Study NCT01783002 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SPECT-CT scanning
Description: For the SPECT-CT scan, each injection of intravenous 99mTc-MIBI is dosed at a maximum of 20 mCi (740MBq), as per usual standard of care. The energy window of each scan is at 140 keV, consistent with the standard of SPEC-CT imaging techniques.
Study NCT02969772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of upper limb variables
Description: International Standards for Neurological and Functional Classification of Spinal Cord Injuries of American Spinal Injury Association (ASIA); Functional Independence Measure (FIM); The following kinematic variables of arm were studied: shoulder, elbow and wrist angles; percentage of time to peak velocity; movement time; peak velocity and movement smoothness (number of velocity peaks and index of curvature); Capabilities of Upper Extremity instrument (CUE); Spinal cord independence measure (SCIM II); electromyography (Clavicular portion of pectoralis major, long head of biceps brachii, anterior and posterior deltoid, triceps and wrist extensors).
Study NCT02969772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training protocol
Description: The strengthening sessions consisted of 20 minutes of electrical stimulation on triceps, extensor carpi radialis longus, extensor digitorum communis, lumbricalis, flexor digitorum superficialis and opponens pollicis muscles. The functional training sessions was performed through movements the reach and palmar grasp with NMES of the several cylindrical and conical objects of different weights (30 minutes sessions).
Study NCT01069952 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation System
Description: In DBS, thin wires are used to carry electric current to the parts of the brain involved in depression symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
Study NCT01852734 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: embolizations ,uterine fibroid
Description: 26 patients will be treat with Bead-block microspheres, 500-700 and 700-900µm until flow stop (  cut the tree appearance)~26 patients will be treat with Embosphere, 500-700µm and /or 700-900 until near stasis  flow stop
Study NCT01852734 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: embolizations
Description: comparison between the two microspheres
Study NCT03329534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten free diet
Description: A month long gluten free diet
Study NCT03329534 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluten free diet
Description: A month long gluten free diet
Study NCT01056094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lutein
Description: Dietary Supplement: 20mg,10mg, 0mg Lutein; daily supplementation 12 week
Study NCT01056094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lutein
Description: Dietary Supplement: 20mg,10mg, 0mg Lutein; daily supplementation 12 week
Study NCT01334684 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Metformin, pills, 850 mg three times a day for three months
Study NCT03916042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID
Description: Reproxalap Opthalmic Solution (0.25% Novel Formulation) administered QID for four weeks, followed by BID administration for eight weeks
Study NCT03916042 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID
Description: Vehicle Ophthalmic Solution administered QID for four weeks, followed by BID administration for eight weeks
Study NCT03314662 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)
Description: The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for quadrivalent vaccines.
Study NCT03314662 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1)
Description: The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines.
Study NCT00642746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Platinum-based antineoplastic chemotherapy agent given intravenously at 85 mg/m2.
Study NCT00642746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Chemotherapy agent given intravenously at 180 mg/m2.
Study NCT01767870 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FIT-sigmoidoscopy
Description: Advanced colorectal adenoma detection by fecal immunochemical test with sigmoidoscopy
Study NCT01767870 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Advanced colorectal adenoma detection by colonoscopy
Study NCT00396149 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two matching placebo tablets were administered every day over 2 weeks with a 2-day break for the week-end.
Study NCT00396149 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rBet v 1
Description: Two tablets (1 placebo + 1 rBet v 1 or 2 rBet v 1) were administered every day over 2 weeks with a 2-day break for the week-end. Administered doses ranged from 50 to 300 µg rBet v 1.
Study NCT01728883 — intervention group
Intervention type: DEVICE
Intervention: Home vision monitoring using myVisionTrack®
Description: Patients will be asked to test their vision at home twice per week using myVisionTrack® during the study period.
Study NCT02480179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: H.E.G. (hematoencephalography) based neurofeedback
Description: H.E.G. is a relatively new neurofeedback technique which, similar to fMRI is based on differential oxygenated blood supply according to regional brain activity.
Study NCT03674203 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma
Description: 1 ml of PRP was distributed in the papillary dermis of the face, repeating the dose at 15 and 30 days.
Study NCT00607958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipranavir/ritonavir (dose reduction)
Description: tipranavir/ritonavir 500/100 BID
Study NCT01970514 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARO Spinal System
Description: The device provides an internal axial rotation orthosis (ARO) for patients being surgically treated for herniated nucleus pulposus (HNP).
Study NCT03220711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: confocal endomicroscope
Description: This instrument provides real-time endoscopic histology to guide endoscopic biopsy or endoscopic mucosal resection (EMR) in the patient study group during colonoscopies.
Study NCT03220711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein
Description: Fluorescent dye used for imaging contrast only.
Study NCT03054948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMOFLipid
Description: SMOFlipid is a lipid emulsion formed using soybean oil, medium chain triglycerides, olive oil, and fish oil.
Study NCT03054948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: In most cases standard therapy will be IntraLipid.
Study NCT00581906 — intervention group
Intervention type: RADIATION
Intervention: DCE-MRI, DW-MRI and MRS
Description: Pts undergo DCE-MRI, DW-MRI or 1\^H-MRS studies on either the 1.5T scanner or the 3T MRI scanners. Patients will be grouped based on their treatment: group one will include pts who undergo surgery (we will no longer accrue pts in this group) \& group two will include pts who undergo chemoradiation therapy.Pts who undergo surgery will have pretreatment DCE-MRI, DW-MRI \&/or 1H-MRS studies on the GE 1.5T or 3T MRI scanner. Pts who participate in chemo-radiation therapy protocols will have pretreatment DCE-MRI, DW-MRI \&/or 1H-MRS studies on the 3T Philips MRI scanner in the radiation oncology suite \& will undergo additional recommended weekly DW-MRI including IVIM studies at the same MRI scanner during the course of treatment. Pts will undergo two recommended DCE-MRI studies (unless contraindicated) when possible. 1st intra-treatment DCE-MRI is recommended between the 1st \& 2nd weeks of treatment \& the 2nd intra-treatment DCE-MRI is recommended between the 3rd \& 4th weeks of treatment.
Study NCT01711684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenylcyclopropenone (DPCP)
Description: Topical application of study drug
Study NCT00473837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: This is an orange syrup in a 60ml amber coloured glass bottle containing 50mg of chloroquine base per 5mls as the chloroquine phosphate. The syrup was manufactured by Medreich Sterilab Ltd, Avalahalli, Bangalore, India. Chloroquine: weekly treatment of 7.5mg/kg for 90 days
Study NCT00473837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is an orange syrup in a 60ml amber coloured glass bottle containing sucrose syrup base. The syrup was prepared by the Pharmacy department of the Royal Victorial Teaching Hospital and Atlantic Pharmaceuticals Limited, Banjul
Study NCT01397448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E3810
Description: E3810 5 mg/day Group: Orally administered E3810 5 mg tablets and E3810 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.
Study NCT01397448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E3810
Description: E3810 10 mg Group: Orally administered E3810 5 mg placebo tablets and 10 mg tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.
Study NCT01397448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teprenone
Description: Teprenone 150 mg/day Group: Orally administered E3810 5 mg placebo tablets and 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg capsules three times daily after each meal.
Study NCT01267383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Sertraline Hydrochloride Tablets 100 mg
Study NCT01267383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Sertraline Hydrochloride Tablets 100 mg
Study NCT02014142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost Punctal Plug Delivery System (L-PPDS)
Description: Latanoprost Punctal Plug Delivery System (L-PPDS)
Study NCT02002052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent platinum-based chemotherapy
Description: Platinum-based concurrent chemotherapy in both arms
Study NCT02002052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent platinum-based chemotherapy
Description: Platinum-based concurrent chemotherapy in both arms
Study NCT02002052 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Radiotherapy, 60 Gy in 30 fractions.
Study NCT02002052 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Functional Lung Avoidance Radiotherapy, 60 Gy in 30 fractions
Study NCT03724578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grape Seed Extract mouth wash
Description: participants will use grape seeds extract mouth wash in addition to standard preventive measures
Study NCT03724578 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: standard preventive measures
Description: twice daily brushing with fluoride tooth pate and daily flossing
Study NCT03724578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antimicrobial and fluoride mouth wash
Description: using chlorhexidine and fluoride containing mouth wash
Study NCT00073684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma focused cognitive behavioral therapy (TF-CBT)
Description: This study aims to: (1) examine the differential effects of CBT with and without trauma narrative interventions; (2) examine the comparative efficacy of brief and extended (8 vs. 16 sessions) individual CBT; (3) make developmental comparisons between 4-7 year olds and 8-11 year olds as to the appropriateness and therapeutic necessity of exposure interventions and longer treatment; and (4) identify child and parent factors that may significantly mediate the relationships between treatment conditions and outcomes. The findings of this study will help establish clinical as well as developmental markers for the early identification of sexually abused children who may require more focused (i.e., including trauma narrative) and/or longer treatment to achieve optimal outcomes.
Study NCT00073684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief abuse-focused treatment
Description: Participants will receive 8 sessions of TF-CBT with abuse-focused treatment.
Study NCT00073684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief coping skills treatment
Description: Participants will receive 8 sessions of TF-CBT with brief coping skills treatment.
Study NCT00073684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended abuse-focused treatment
Description: Participants will receive 16 sessions of TF-CBT with extended abuse-focused treatment.
Study NCT00073684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended coping skills treatment
Description: Participants will receive 16 sessions of TF-CBT with extended coping skills treatment.
Study NCT04149548 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound
Description: Obstetric ultrasound to pregnant women
Study NCT03496103 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: ragweed pollen
Description: three hours ragweed pollen in a allergen exposure chamber
Study NCT00226772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS103HP
Description: Maximum of 39 liters of OMS103HP irrigation solution over a maximum of 2 hours
Study NCT00226772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Maximum of 39 liters of vehicle irrigation solution over a maximum of 2 hours
Study NCT04050644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative Free drop treatment
Description: Patients will use the preservative-free dexamethasone 0.1% 4 times a day in the first week after cataract surgery, 3 times a day in the second week, twice daily in the third week and once daily in the fourth week and diclofenac 0.1% eye drops 3 times daily for 1 day preoperatively and every 15 minutes in the hour before surgery and then 3 times a day for four weeks.
Study NCT04050644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preserved drop treatment
Description: Patients will use the preserved dexamethasone 0.1% 4 times a day in the first week after cataract surgery, 3 times a day in the second week, twice daily in the third week and once daily in the fourth week and diclofenac 0.1% eye drops 3 times daily for 1 day preoperatively and every 15 minutes in the hour before surgery and then 3 times a day for four weeks.
Study NCT00825084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: dose escalation of single oral doses of 5, 10 and 20 mg
Study NCT00825084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: 10 mg TID of Dimebon for 7 days followed by 20 mg TID of Dimebon for 7 days
Study NCT02794194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive training on a whole body vibration platform
Description: The Training programme consisted of three series of 4 exercises of 45 seconds with 45 seconds rest between exercises. In this intervention participants trained with the BOSU® on a Fitvibe Excel Pro vibration platform (Fitvibe, Bilzen, Belgium).
Study NCT02794194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive training with the BOSU® on the floor
Description: The Training programme consisted of three series of 4 exercises of 45 seconds with 45 seconds rest between exercises. In this intervention participants trained with the BOSU® on the floor.
Study NCT00768235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: yoga practice
Description: The yoga program comprised 70 min sessions, 3 times/week during 12 weeks
Study NCT02271854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diclofenac sodium gel 1%
Description: Diclofenac sodium gel 1% four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
Study NCT02271854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium gel 1%
Description: Diclofenac sodium gel 1% four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
Study NCT02029352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinecatechins 10%
Study NCT02029352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Composition, apart from the active substance, is otherwise identical to the investigational medical product.
Study NCT02303951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Run-In: Day 1-21 960 mg bid orally, Day 22-28 720 mg bid orally Triple-Treatment (week 5 ongoing): 720 mg bid orally
Study NCT02271854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
Study NCT02271854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo gel four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).